According to a study, Barber and colleagues devised a chimeric receptor by fusing NKG2D to the CD3ζ of the TCR, and genetically engineered T cells to express this receptor, and demonstrated that the engineered T cells exhibited tumoricidal reactivity and secreted proinflammatory cytokines upon engagement of their engineered receptors with NKG2DLs (which were surface-expressed by more than 80% of human ovarian cancer biological samples, and the ovarian cancer cell lines A2780 and A2008) (122). Here, KLRK1 is linked to ovarian cancer.